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Abstract. The mammalian or mechanistic target of rapamycin 
(mTOR) is a Ser/Thr protein kinase that, in response to nutrient 
stimulation, regulates cellular growth, proliferation, survival, 
protein synthesis and gene transcription. It has also been 
implicated in Alzheimer's disease (AD) with neuronal cells 
and hippocampal slices of AD transgenic mice experiencing 
dysregulated mTOR and synaptic plasticity in response to treat-
ment with the toxic amyloid β (Aβ1-42) peptide, which has been 
implicated in AD. DEP domain-containing mTOR-interacting 
protein (DEPTOR) is a protein which can bind to mTOR and 
cause its inhibition, and functions as a regulatory protein of 
mTOR to control its activity. The inhibition of mTOR has been 
shown to have a neuroprotective effect; in an animal model, it 
was shown to protect against Aβ-induced neurotoxicity. In the 
present study, to investigate to role of DEPTOR in a model of 
AD, we neuronally differentiated the SH-SY5Y cell line and 
examined the effects of treatment with an Aβ42 peptide, thus 
mimicking plaque formation. This resulted in a significant 
increase in mTOR and a significant decrease in DEPTOR 
expression compared to the unstimulated controls. Moreover, 
to the best of our knowledge, we demonstrate for the first time 
a reduction in the protein level of DEPTOR in the precentral 
gyrus, postcentral gyrus and occipital lobe of a brain with AD 
compared to a normal control, as well as a significant reduc-
tion in DEPTOR expression in samples from late-onset AD 
(LOAD) compared to early-onset familial AD (EOFAD). The 
reduction in DEPTOR expression in cases of AD compared 
to healthy controls can lead to an augmentation of mTOR 
signalling, leading to Aβ accumulation, which in turn leads 
to a further reduction in DEPTOR expression. This results in 
the accumulation of amyloid plaque, shifting the balance from 
neuroprotection to neurodegeneration.
Introduction
The pathogenesis of Alzheimer's disease (AD) is multi-aetiolog-
ical, and it is likely due to these various origins that AD induces 
diverse neuropathological changes. The most prominent lesions 
in brains with AD are atrophy, a large number of senile plaques 
(SPs) formed by amyloid β (Aβ) between neurons and neurofibril-
lary tangles (NFTs) made of abnormally hyperphosphorylated 
tau protein in neurons (1). Several other mechanisms have also 
been proposed to explain the pathogenesis of AD. Although 
each of these mechanisms may contribute to the pathogenesis 
of the disease, the extent to which they drive the neurodegen-
erative process is uncertain (2). This is further complicated by 
the fact that two different pathways are detected in neurons, 
i.e., neurodegeneration and neurofibrillary degeneration. 
Neurodegeneration incorporates different abnormal signalling 
pathways that lead to neuronal loss, including apoptosis and 
other modes of cell death. Neurofibrillary degeneration is a 
specific type of neuronal reaction marked by the accumulation 
of hyperphosphorylated tau protein as paired helical filaments 
in NFTs, which can also induce abnormal neuronal metabolism 
and death. Of note, these two pathways share mTOR-dependent 
signalling as a common key regulator (1).
The mammalian or mechanistic target of rapamycin 
(mTOR) is a Ser/Thr protein kinase that functions as an 
adenosine triphosphate (ATP) and amino acid sensor to balance 
nutrient availability and cell growth (3,4). mTOR is capable of 
forming two complexes named mTORC1 and mTORC2 (5). The 
rapamycin-sensitive mTORC1 contains the following proteins: 
raptor, GβL (also known as mLST8) and the proline-rich 
Akt substrate of 40 kDa (PRAS40). The mTORC2 complex 
contains rictor, mamalian stress-activated protein kinase 
(SAPK)-interacting protein 1 (mSIN1), Protor-1 and GβL5 (5). 
A number of recent studies have found a strong link between 
mTOR and AD. For example, mTOR is critical for long-lasting 
forms of synaptic plasticity and long-term memory (LTM) 
formation, which is impaired in mouse models of AD (6). The 
importance of mTOR in synaptic plasticity is in agreement with 
the central role of mTOR in controlling transcriptional events, 
since de novo protein synthesis is involved in these long-lasting 
forms of synaptic plasticity and LTM (7). The inhibition of the 
mTOR pathway appears to modulate the process of aging, a 
well-established risk factor for AD (8,9). Moreover, autophagy, a 
pathway for organelle and protein turnover, has been implicated 
in neurodegeneration. Autophagy is constitutively active and 
highly efficient in healthy neurons and rapamycin (an mTOR 
inhibitor) is able to induce autophagy (10). Finally, mTOR 
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signalling has been shown to be altered in models of AD (11,12). 
mTOR signalling has been shown to be inhibited both in 
cultured neurons and hippocampal slices from AD transgenic 
mice and in wild-type (WT) hippocampal slices exposed to 
exogenous Aβ1-42, and this mTOR dysregulation correlates with 
impairment in synaptic plasticity (13).
Recently, a novel endogenous inhibitor of the mTOR 
pathway, termed DEP domain-containing mTOR-interacting 
protein (DEPTOR), has been shown to bind to both the 
mTORC1 and mTORC2 complexes (14). Its precise func-
tion has not yet been fully elucidated; however, knocking 
down DEPTOR leads to the activation of signalling through 
mTORC1 and mTORC2. This is demonstrated both by the 
observation that there is a change in the phosphorylation 
status of S6 kinase 1 (S6K1) and protein kinase B (PKB) when 
DEPTOR levels are decreased (by RNA-based interference) 
and by the increased in vitro activity against these substrates 
of mTOR complexes from cells with decreased levels of 
DEPTOR (14,15). Moreover, DEPTOR has been shown to be 
downregulated in malignancies of the prostate, bladder, head 
and neck, cervix and thyroid (14), whereas we have previously 
demonstrated the significant upregulation of DEPTOR in two 
paclitaxel-resistant ovarian cancer cell lines when compared 
to the parental ones (16). Evidence of the potential involvement 
of DEPTOR in AD arises from studies in which resveratrol 
(RSV), a naturally occurring polyphenol, has been used. 
RSV inhibits mTOR signalling by promoting the interaction 
between mTOR and DEPTOR in vitro (17). Recent studies have 
indicated that RSV has neuroprotective properties (18,19). In 
an animal model, RSV has been shown to protect rats from 
Aβ-induced neurotoxicity (20).
Emerging data suggest that the augmentation of mTOR 
signalling is involved in the aetiopathogenesis of AD. We 
hypothesised that DEPTOR is an integral modulator of both 
the mTORC1 and mTORC2 complexes, and the presence or 
degree of binding to the complexes may determine at which 
point mTOR will be inhibited/activated, thus leading to a 
neuroprotective or neurotoxic effect.
Materials and methods
Cell culture. SH-SY5Y cells (ATCC; Manassas, VA, USA) 
were cultured in 1:1 EMEM and Hams F12 (Sigma-Aldrich, 
Gillingham, UK) supplemeted with 10% FBS (50 ml; Gibco, 
Paisley, UK), 1% non-essential amino acids, 1% 200 mM 
L-glutamine, 1% penicillin/streptomycin (Gibco) at 37˚C with 
5% CO2. The SH-SY5Y cells were neuronally differentiated 
for 6 days by treatment with 10 µM retinoic acid (RA) (Sigma-
Aldrich).
Quantitative RT-PCR. Anterior hippocampus with entorhinal 
cortex samples from adults with AD [n=10; 5 with early-onset 
familial AD (EOFAD); median age, 61 years; and 5 with 
late-onset AD (LOAD); median age, 84 years] were provided 
in collaboration with Brains for Dementia Research (BDR), 
University of Newcastle, Newcastle upon Tyne, UK. The relative 
expression of the genes of interest was assessed by quantitative 
PCR (qPCR) on an ABI PRISM® 7900HT Sequence detec-
tion system (Applied Biosystems, Foster City, CA, USA) using 
SYBR®-Green PCR reaction mixture (Sigma-Aldrich) and the 
primers for mTOR and DEPTOR as previously described (21). 
As a negative control for all the reactions, distilled water 
was used in place of the cDNA. RNAs were assayed from 
3 independent biological replicates. The RNA levels were 
expressed as a relative quantification using the housekeeping 
gene, 18S rRNA (RQ) value. The ΔCt method was employed 
for comparing relative expression results between treatments 
in qPCR, as previously described (22).
Western blot analysis. Protein lysates in 1X Laemmli buffer 
(Sigma-Aldrich) were separated on an SDS-10% polyacrylamide 
gel (Sigma-Aldrich) and the proteins were transferred onto 
nitrocellulose membranes (GE Healthcare, Buckinghamshire, 
UK). The membranes were blocked in TBS (Fisher Scientific, 
Loughborough, UK) containing 5% dried milk powder 
(w/v) and 0.1% Tween‑20 (Fisher Scientific), for 1 h at room 
temperature. Following 3 washes with TBS-0.1% Tween-20, 
the nitrocellulose membranes were incubated with primary 
antibodies against Aβ42 and GAPDH (both from Cell Signalling 
Technology, Danvers, MA, USA). The primary antisera were 
used at a 1:1,000 dilution overnight at 4˚C. The membranes were 
washed thoroughly for 30 min with TBS-0.1% Tween-20 prior 
to incubation with the secondary antibody, HRP-conjugated 
immunoglobulin (1:2,000; Sigma-Aldrich), for 1 h at room 
temperature and further washing for 30 min with TBS-0.1% 
Tween-20. Antibody complexes were visualised as previously 
described (21).
Immunofluorescence staining of AD sections. Three brain 
regions (precentral gyrus, postcentral gyrus and occipital lobe) 
from a single brain with AD and a normal brain were obtained 
as a tissue microarray from LifeSpan Biosciences Inc. (LSBio; 
Seattle, WA, USA). The ages of the patients were 75 and 54 years, 
respectively, and they were both male. Following a series of 
deparaffinisations and dehydrations, the slides were incubated 
with 10% bovine serum albumin (BSA; Sigma-Aldrich) for 1 h. 
This was followed by incubation for 1 h with an antibody against 
DEPTOR (Millipore, Abingdon, UK), at a 1,200 dilution in 1% 
BSA/PBS. The cells were then washed with PBS prior to an 
incubation with a fluorescein isothiocyanate (FITC)‑conjugated 
secondary antibody (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) for 1 h. The slides were washed with PBS 
and mounted in VECTASHIELD® Mounting Medium (Vector 
Laboratories, Inc., Burlingame, CA, USA) containing the dye, 
4,6-diamido-2-phenylindole (DAPI) to counterstain the nuclei. 
Images were captured using a Plan Apo Neofluar 63X NA 1.25 
oil objective (Zeiss, Thornwood, NY, USA) on a Zeiss Axiovert 
200 M microscope and viewed using AxioVision software. The 
images were then analyzed using ImageJ 1.34 image analysis 
software (National Institutes of Health, Bethesda, MD, USA).
Immunofluorescence staining of SH-SY5Y cells. The neuronally 
differentiated SH‑SY5Y cells were fixed in 4% paraformalde-
hyde (Sigma-Aldrich) for 10 min prior to washes in PBS and 
incubation with 10% BSA for 1 h. The cells were incubated for 1 h 
with DEPTOR (Millipore), mTOR (Cell Signalling Technology) 
and pan-neuronal marker (Millipore) antibodies at a 1:100 dilu-
tion in 1% BSA/PBS. The cells were then washed with PBS prior 
to a further incubation with secondary antibodies as previously 
described (21). Images were captured using a Plan Apo Neofluar 
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63X NA 1.25 oil objective (Zeiss) on a Zeiss Axiovert 200 M 
microscope and viewed using AxioVision software.
Statistical analysis. qPCR data are reported as the 
means ± standard error of the mean (SEM). Statistical analysis 
was performed using the Student's t-test. A value of p<0.05 
was considered to indicate a statistically significant difference.
Results
Development of an in vitro neuronal model. The morpho-
logical changes of the SH-SY5Y were monitored during the 
differentiation process using a microscope. The SH-SY5Y 
cells were seeded at 1x106 and the undifferentiated SH-SY5Y 
cells were fast-growing and rounded in shape (Fig. 1A). 
Following differentiation, the cells did not reach confluence 
and by day 6, neurite extensions were prominent (Fig. 1B). A 
pan-neuronal marker was then used in the differentiated and 
undifferentiated cells in order to observe the changes occur-
ring in fundamental somatic, nuclear, dendritic and axonal 
proteins. In the undifferentiated cells, there was a low expres-
sion of neuronal proteins, as SH-SY5Y is a neuroblastoma cell 
line (Fig. 1C). Following differentiation using RA for 6 days, 
the SH-SY5Y cells demonstrated a notable increase in the 
pan-neuronal marker signal, further confirming the acquisi-
tion of a neuronal phenotype (Fig. 1D). We then assessed the 
protein expression of mTOR and DEPTOR in the neuronally 
differentiated cells. Using immunofluorescence, an intense 
cytoplasmic staining was observed for both mTOR (Fig. 1E) 
and DEPTOR (Fig. 1F).
Treatment of differentiated SH-SY5Y cells with Aβ42 to mimic 
an AD milieu in vitro: effects on mTOR and DEPTOR. As 
already mentioned in the Introduction, one of the hallmarks of 
AD is the large number of SPs formed by an accumulation of 
toxic Aβ between neurons. Aβ42 in patients with AD has been 
shown to reach concentrations lower than 10 nM, but can reach 
µM ranges (23-25). Our aim was to treat fully differentiated 
SH-SY5Y cells with 1 µM Aβ42 in an attempt to mimic an AD 
milieu and assess its effects on mTOR and DEPTOR expres-
sion in vitro. Western blot analysis was performed to ensure that 
Aβ42 was being deposited. In the cells treated with Aβ42, there 
was protein deposition which was detected at 4 kDa (Fig. 2A). 
Fully differentiated SH-SY5Y cells were seeded at a density of 
1x105/well, serum-starved for 4 h and treated with Aβ42 (1 µM) 
for 24 h. mTOR epxression was markedly increased (2-fold) 
Figure 1. Retinoic acid (RA)-induced differentiation of SH-SY5Y cells for 6 days with 10 µM RA. (A) Cell microscopy of undifferentiated cells and (B) dif-
ferentiated cells. Immunofluorence staining of cells using a PanNeuronal Marker (C) before and (D) after neuronal differentiation. Mechanistic target of 
rapamycin (mTOR) expression (E) shown by immunofluorence staining and (F) with a DEPTOR antibody in differentiated SH-SY5Y cells.
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upon 24 h of Aβ42 treatment, whereas DEPTOR expression 
was markedly decreased compared to the control (Fig. 2B).
Differential expression of DEPTOR in brains with AD. We 
then assessed the protein expression of DEPTOR from 3 brain 
regions from a single brain with AD and a normal (healthy) 
brain. The ages of the patients were of 75 and 54 years, respec-
tively, and they were both male. In all 3 different regions, 
i.e., precentral gyrus, postcentral gyrus and occipital lobe, 
the expression of DEPTOR was markedly decreased in the 
patient with AD compared to the same region of the healthy 
control (Fig. 3A).
Using clinical samples from patients with EOFAD (median 
age, 61 years) and LOAD (median age, 84 years) we examined 
the expression of DEPTOR at the mRNA level using qPCR. 
There was a significant (~4‑fold) decrease in the expression of 
DEPTOR in the patients with LOAD when compared with the 
patients with EOFAD (Fig. 3B).
Discussion
To the best of our knowledge, in this study, we demonstrate for 
first time the expression of DEPTOR in human brains, as well 
as the mechanisms through which its expression is affected by 
Aβ42 accumulation. Several disease mechanisms involved in 
AD affect the structure, as well as the signalling experienced 
by neurons; thus, it is essential to obtain a model that is more 
similar to an in vivo situation so as to study more comparable 
results. Immortalised cell lines are an appropriate solution to 
study this; however, they lack some of the key characteristics 
Figure 2. Differentiated SH-SY5Y cells were treated with an amyloid β (Aβ)42 peptide. (A) Western blot analysis of extracted protein revealed that, in the 
control (lane 1), there was no Aβ42 deposition, but with Aβ42 treatment there was an accumulation of the peptide detected at 4 kDa (lane 2). (B) Quantitative 
polymerase chain reaction (qPCR) of cells treated with Aβ42 revealed a significant increase in mechanistic target of rapamycin (mTOR) expression compared to 
the untreated cells and a significant reduction in DEPTOR expression over 24 h. Data are the means ± standard error of the mean (SEM). *P<0.05, stastistically 
significant difference compared to the untreated control samples (n=3).
Figure 3. (A) Immunohistochemical staining with a DEPTOR antibody revealed a reduction in its expression in the precentral gyrus, postcentral gyrus and 
occipital lobe of a brain with Alzheimer's disease (AD) compared to a healthy control brain. (B) DEPTOR expression levels in human late onset AD (LOAD) 
samples were significantly reduced compared to early onset familial AD (EOFAD) samples. Data are the means ± standard error of the mean (SEM). *P<0.05, 
stastistically significant difference between LOAD and EOFAD (n=5).
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of human neurons, such as morphology, cessation of mitosis 
and the expression of neuronal markers. The transition to a 
more neuronal phenotype is vital for mimicking a disease or 
a signalling milieu in vitro. Due to extensive study previously 
performed on SH-SY5Y cells, combined with the comprehen-
sive use of this cell line in previous research on AD, we decided 
that this would be the most appropriate cell line to use (26,27). 
Neuronal differentiation was accomplished by the addition 
of RA and validated by observing cell morphology, neurite 
extension and the expression of neuronal proteins. In this 
model, both mTOR and DEPTOR appeared to be expressed 
at the protein level, mainly localised in the cytoplasm. This 
finding corroborates findings from previous studies performed 
in our laboratory, demonstrating that the cellular distribution 
of mTOR is primarily cytoplasmic (21). mTOR can also shuttle 
between the nucleus and cytoplasm (28), and in the SH-SY5Y 
cells, DEPTOR was also primarily localised in the cytoplasm; 
however, there was some immunofluorescence staining in the 
nucleus. This could be suggestive of potential trafficking to the 
nucleus alone or as part of the mTORC1 complex.
As already mentioned, one of most important hallmarks 
of AD is the accumulation of Aβ42, causing the formation of 
Aβ plaques. When the SH-SY5Y cells were treated with the 
‘toxic’ Aβ42 peptide, this led to a decrease in the expression of 
DEPTOR and a marked upregulation in mTOR gene expres-
sion. This is the first time that Aβ42 appears to differentially 
affect key mTOR signalling components in vitro. We then 
expanded our observations using clinical samples, where 
there was a notable decrease in DEPTOR immunostaining 
in certain regions of the brain with AD when compared to a 
healthy control. This is of increasing importance, as micro-
structural damage to the precentral gyrus of patients with 
AD, as well as a thinning of the postcentral gyrus, have been 
recently demonstrated (29,30). It is also thought that damage 
incurred by the occipital lobe in AD can greatly contribute 
to psychotic symptoms, as a result of deficits in attention and 
visual systems (31,32).
We also provide novel data regarding the differential 
expression of DEPTOR in early- and late-onset AD. It is 
evident that, in LOAD, there is a marked downregulation 
in DEPTOR expression, in agreement with the diminished 
expression of this protein in brain regions with AD. EOFAD 
presents before 65 years of age and there are multiple cases 
within a family usually attributable to mutations in the 
amyloid precursor protein (APP) gene, the presenilin (PSEN)1 
gene or the PSEN2 gene (33). By contrast, LOAD occurs after 
65 years of age and is sporadic with no known single targetable 
cause (34). We would like to acknowledge that, due to ethical 
restrictions, we were unable to obtain more brain samples in 
order to investigate the expression and cellular distribution of 
other components of the mTOR signalling pathway.
Our study provides new insight into the higher order of 
complexity regarding the involvement of DEPTOR and mTOR 
in the aetiopathogenesis of AD. Caccamo et al (35) demon-
strated that Aβ accumulation causes mTOR hyperactivity by 
regulating PRAS40 phosphorylation, whereas RSV promotes 
the non-amyloidogenic cleavage of the amyloid precursor 
protein, the enhanced clearance of Aβ-peptides and reduced 
neuronal damage (19). Of note, RSV exerts its effects by 
tightly complexing DEPTOR with mTOR. DEPTOR deple-
tion enhances the in vitro kinase activity of the mTORC1 and 
mTORC2 complexes. More specifically, mTORC1 immunopu-
rified from cells depleted of DEPTOR has increased in vitro 
kinase activity towards two known substrates, S6K1 and 
4EBP1. Of note, these molecules control the synthesis of β- or 
α‑secretase and, therefore, Aβ generation (36).
Treatment of differentiated mouse N2a neuroblastoma 
cells with Aβ42 has been shown to induce the phosphorylation 
of mTOR at S2448 and of p70S6K at T38927. Similarly, in 
differentiated human SH‑SY5Y neuroblastoma cells, a signifi-
cant upregulation of p-p70S6K at T389 and T421/S424 sites 
was induced following treatment with Aβ42 (11).
Taken together, we would l ike to propose the 
following (Fig. 4) that builds upon the model proposal shown 
in the study by Cai et al (36): under normal conditions, mTOR 
activity is modulated by DEPTOR. This will allow autopha-
gosomes to clear any toxic Aβ oligomers, thus favouring 
a neuroprotective environment. In patients with AD, the 
Figure 4. Proposed model for the interaction of the mechanistic target of rapamycin (mTOR)/DEPTOR in a normal brain and a brain with Alzheimer's disease (AD).
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mTOR pathway can be overactive, leading to a dysfunction of 
autophagy and, consequently, a lack of Aβ clearance. In turn, 
the excess of Aβ will cause a further decrease in DEPTOR and 
an increase in mTOR expression, augmenting the neurodegen-
erative process.
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